Optimisation of the assays for the measurement of clotting factor activity in the presence of rivaroxaban

Thrombosis Research

Volumn 129, Issue 1, 2012, Pages 101-103

  Gerotziafas, Grigoris T ^a,b   Baccouche, Hela ^a,b   Sassi, Mouna ^a,b   Galea, Vassiliki ^a,b   Chaari, Mourad ^a,b   Hatmi, Mohamed ^b   Samama, Meyer M ^c   Elalamy, Ismail ^a,b  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; FIBRINOGEN; RIVAROXABAN;

ASSAY; BLOOD CLOTTING; HUMAN; HUMAN EXPERIMENT; LETTER; NORMAL HUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; THROMBOCYTE POOR PLASMA;

ANTICOAGULANTS; BIOLOGICAL MARKERS; BLOOD COAGULATION; BLOOD COAGULATION FACTORS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MORPHOLINES; PARTIAL THROMBOPLASTIN TIME; PREDICTIVE VALUE OF TESTS; PROTHROMBIN TIME; REPRODUCIBILITY OF RESULTS; THIOPHENES; TIME FACTORS;

EID: 84655163143     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2011.09.004     Document Type: Letter

References (7)

1. E. Perzborn, S. Roehrig, A. Straub, D. Kubitza, W. Mueck, and V. Laux Rivaroxaban: a new oral factor Xa inhibitor Arterioscler Thromb Vasc Biol 30 2010 376 381
2. W. Mueck, L.C. Borris, O.E. Dahl, S. Haas, M.V. Huisman, and A.K. Kakkar Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement Thromb Haemost 100 2008 453 461
3. J. Jiang, Y. Hu, J. Zhang, J. Yang, W. Mueck, and D. Kubitza Safety, pharmacokinetics and pharmacodynamics of single doses of rivaroxaban - an oral, direct factor Xa inhibitor - in elderly Chinese subjects Thromb Haemost 103 2010 234 241
4. M.M. Samama, and G.T. Gerotziafas Newer anticoagulants in 2009 J Thromb Thrombolysis 29 2010 92 104
5. M.R. Patel, K.W. Mahaffey, J. Garg, G. Pan, D.E. Singer, and W. Hacke Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation N Engl J Med 365 2011 883 891
6. D. Kubitza, M. Becka, G. Wensing, B. Voith, and M. Zuehlsdorf Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct Factor Xa inhibitor-after multiple dosing in healthy male subjects Eur J Clin Pharmacol 61 2005 873 880 (Pubitemid 41803696)
7. M.M. Samama, J.L. Martinoli, L. LeFlem, C. Guinet, G. Plu-Bureau, and F. Depasse Assessment of laboratory assays to measure rivaroxaban-an oral, direct factor Xa inhibitor Thromb Haemost 103 2010 815 825